Loading organizations...

Evolve Biosystems is a technology company.
Evolve Biosystems, operating today as Infinant Health, delivers microbiome-based solutions for infant well-being. Its flagship product, Evivo, is a specialized probiotic utilizing Bifidobacterium infantis EVC001. This formulation is designed to establish a protective gut microbiome in newborns, actively addressing infant gut dysbiosis and fostering the healthy development of the immune system.
The company emerged in 2012 from the research of University of California, Davis scientists Bruce German, David Mills, Carlito Lebrilla, Daniela Barile, and Samara Freeman. Their foundational insight arose from extensive academic work, revealing the crucial importance of a healthy infant microbiome and identifying beneficial bacteria often absent in modern infants.
Infinant Health’s offerings target newborns and young babies, aiming to positively influence their early health trajectory. The company’s overarching vision is to apply its scientific leadership in the microbiome to enhance human health, commencing in infancy, by ensuring a robust gut microbiome for improved lifelong outcomes.
Evolve Biosystems has raised $124.0M across 4 funding rounds.
Evolve Biosystems has raised $124.0M in total across 4 funding rounds.
Evolve BioSystems is a privately-held microbiome technology company focused on infant health, developing products like the probiotic Evivo to restore key gut bacteria missing in modern infants, addressing Newborn Gut Deficiency and reducing risks of conditions such as colic, eczema, allergies, Type 1 diabetes, and NEC.[1][2][4] It serves parents, healthcare providers, and infants worldwide—particularly those on breast milk or formula—by promoting healthy gut, immune, and metabolic development through its lead strain B. infantis EVC001, which cuts pathogenic bacteria by 80% and inflammation.[2][3][4] The company has shown strong growth with over $190M in total funding, including a $65M round, backed by investors like Cargill, Bill & Melinda Gates Foundation, Horizons Ventures, and Manna Tree; it recently rebranded to Infinant Health to expand into specialized microbial products, drugs, and digital health devices.[2][3][6]
Evolve BioSystems emerged as a 2011 spin-off from the Foods for Health Institute at the University of California, Davis, building on over a decade of research into the symbiotic relationship between ancestral Bifidobacterium infantis strains—now rare in developed nations—and human breast milk.[1][2][3] Founders leveraged labs analyzing infant stool samples to pioneer microbiome restoration, achieving early proof-of-concept with Evivo's clinical validation in reducing gut dysbiosis.[2][6] Pivotal moments include a 2021 strategic investment from Cargill for scaling, Bill & Melinda Gates Foundation backing in 2018 for trials in malnourished infants in Bangladesh, and the recent rebrand to Infinant Health under CEO Kaile Zagger, marking a shift to a broader healthcare platform.[2][3][5]
Evolve BioSystems rides the microbiome therapeutics wave, targeting the global rise in infant gut dysbiosis from C-sections, antibiotics, and formula—linked to surging non-communicable diseases amid modern lifestyles.[1][2][4] Timing aligns with precision medicine advances and parental demand for proactive health, amplified by post-pandemic focus on immunity; market forces like aging populations and malnutrition in developing regions favor its scalable probiotics.[2][5] It influences the ecosystem by validating microbiome science commercially, partnering with giants like Cargill and Gates Foundation to bridge research-to-market gaps, and pioneering infant-focused biotech that could prevent lifelong diseases at scale.[2][3]
Infinant Health (formerly Evolve) is poised to dominate infant microbiome care, pushing Evivo as standard-of-care while launching a pipeline of drugs, devices, and AI-driven discoveries to tackle immunity, cognition, and metabolism.[3][4] Trends like personalized nutrition, global malnutrition trials, and regulatory nods for probiotics will accelerate growth, potentially expanding to adult applications. Its influence could reshape preventive pediatrics, tying back to its Davis roots in "baby poop" labs—proving one strain can set humanity's health trajectory from day one.[1][3]
Evolve Biosystems has raised $124.0M in total across 4 funding rounds.
Evolve Biosystems's investors include Cargill, Manna Tree, Bill & Melinda Gates Foundation, Horizons Ventures, Acre Venture Partners, Alta Ventures, Arla Foods, Bow Capital, Continental Grain Company, Johnson & Johnson Innovation, Spruce Ventures, Tate & Lyle Ventures.
Evolve Biosystems has raised $124.0M across 4 funding rounds. Most recently, it raised $55.0M Series D in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 9, 2021 | $55.0M Series D | Cargill, Manna Tree | |
| Jun 1, 2018 | $40.0M Series C | Bill & Melinda Gates Foundation, Horizons Ventures | Acre Venture Partners, Alta Ventures, Arla Foods, Bow Capital, Continental Grain Company, Johnson & Johnson Innovation, Spruce Ventures, Tate & Lyle Ventures |
| May 1, 2017 | $20.0M Series B | Roger W. | Acre Venture Partners, Bow Capital, DBL Partners, Andrew Wheeler, Randy Komisar, Horizons Ventures, Tate & Lyle Ventures |
| Aug 17, 2015 | $9.0M Series A | Anne Lo | Simon Barnes |